Dow Up0.51% Nasdaq Up0.24%

Repros Therapeutics Inc. (RPRX)

8.79 Down 0.19(2.12%) 4:00PM EST
ProfileGet Profile for:
Repros Therapeutics Inc.
2408 Timberloch Place
Suite B-7
The Woodlands, TX 77380
United States - Map
Phone: 281-719-3400
Fax: 281-719-3446

Index Membership:N/A
Full Time Employees:28

Business Summary 

Repros Therapeutics Inc., a development stage biopharmaceutical company, focuses on the development of new drugs to treat hormonal and reproductive system disorders in the United States. Its product portfolio includes Androxal, an oral therapy, which is in Phase III clinical trials for the treatment of low testosterone due to secondary hypogonadism; and Proellex that is in Phase II clinical trials for the treatment of symptoms associated with uterine fibroids and endometriosis. The company has a license agreement with the National Institutes of Health to develop and commercialize Proellex. Repros Therapeutics Inc. was founded in 1987 and is based in The Woodlands, Texas.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Repros Therapeutics Inc.

Corporate Governance 
Repros Therapeutics Inc.’s ISS Governance QuickScore as of Nov 1, 2014 is 8. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 7; Compensation: 8.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Mr. Joseph S. Podolski , 67
Chief Exec. Officer, Pres and Director
Ms. Katherine A. Anderson CPA, 56
Chief Financial Officer, Chief Accounting Officer and Sec.
Dr. Jaye L. Thompson Ph.D., 48
Sr. VP of Clinical & Regulatory
Dr. Joachim F. Wernicke M.D., Ph.D., 66
Chief Medical Officer
Dr. Ronald Wiehle Ph.D., DSC, 65
VP of R&D
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders